Telehealth Weight Loss/GLP-1 Prescribing: What PMHNPs Can Do in California

If you’re a psychiatrist or PMHNP watching the GLP-1 boom and wondering whether prescribing weight loss medications fits your practice, you’re not alone. The question isn’t just ‘Can I do this legally?’ — it’s ‘Should I, and what’s actually involved?’

Here’s the reality: Many of your psychiatric patients are already asking about Ozempic, Wegovy, or Mounjaro. They’re dealing with antipsychotic-induced weight gain, metabolic syndrome from years of mood stabilizers, or co-occurring obesity that’s worsening their depression. The lines between psychiatric care and metabolic health are blurring — and that creates both an opportunity and a compliance minefield.

This guide cuts through the noise. We’ll cover:

• Whether prescribing weight loss medications falls within your scope of practice (spoiler: it can, with caveats)
• The dramatic differences between what MDs and PMHNPs can prescribe state-by-state
• Telehealth prescribing rules that could land you in hot water if you get them wrong
• What insurance actually covers and how to get paid
• State-specific regulations in California, Texas, Florida, New York, Pennsylvania, and Illinois

No fluff. Let’s get into it.

Do Psychiatrists Have the Authority to Prescribe Weight Loss Medications?

Short answer: Yes, psychiatrists (MD/DO) have full prescriptive authority to write for FDA-approved weight loss medications and GLP-1 agonists in all 50 states. Your medical license and DEA registration cover it.

The nuanced answer: Just because you can doesn’t mean you should without proper preparation. Scope of practice isn’t just about legal authority — it’s about competency.

The Scope Question: Is This ‘Psychiatric Practice’?

The traditional objection goes: ‘Weight management is primary care or endocrinology territory, not psychiatry.’ But that’s becoming outdated thinking. Here’s why:

Psychiatrists already manage metabolic issues. You monitor lipids, glucose, and weight for patients on atypical antipsychotics. You prescribe stimulants (which affect appetite and metabolism). You treat binge eating disorder. Managing obesity with medications like semaglutide isn’t a leap — it’s a natural extension when you’re already addressing medication-induced weight gain or co-occurring metabolic dysfunction.

Dr. Elliott Lewis, a psychiatrist who’s also board-certified in obesity medicine, puts it directly: ‘If we truly understand that these systems are inseparable, then psychiatrists being involved in metabolic treatment makes complete sense.’ The brain-body connection isn’t theoretical anymore — GLP-1 receptors exist throughout the CNS, and these medications may even have direct neuropsychiatric effects (potentially reducing cravings, improving mood independent of weight loss).

The key is documented competency. You can’t just start writing Wegovy scripts after a 5-minute Google search. But if you:

• Complete focused CME on obesity pharmacotherapy (understanding mechanism, contraindications, titration schedules, side effect management)
• Familiarize yourself with metabolic workups (when to order thyroid panels, A1C, lipids, rule out secondary causes of obesity)
• Consider pursuing American Board of Obesity Medicine (ABOM) certification (yes, psychiatrists are eligible)

…then you’re operating well within a defensible scope. ABOM certification involves ~60 hours of obesity-focused education and passing a board exam — it’s a concrete way to silence any scope-of-practice criticism from colleagues or medical boards.

What About Safety? The Suicidality Question

The elephant in the room: You’ve seen headlines about GLP-1s and suicide risk. Should psychiatrists be concerned?

Current evidence is reassuring. A 2025 meta-analysis in JAMA Psychiatry found no increase in depression or suicidal ideation with GLP-1 medications versus placebo. The FDA and EMA both reviewed the data and concluded there’s no causal link. In fact, the STEP trials (semaglutide for weight loss) showed slightly lower rates of depressive symptoms in the GLP-1 group compared to controls.

This makes sense when you consider the mechanism: these aren’t CNS stimulants or drugs with direct psychotropic effects. They’re incretin mimetics working primarily on satiety pathways. Any mood improvement is likely indirect (weight loss → improved self-esteem and physical health → better mental health outcomes).

Your advantage as a psychiatrist: You’re uniquely qualified to monitor for psychiatric side effects, manage pre-existing mental health conditions while starting weight loss treatment, and address the psychological components of obesity (emotional eating, body image issues, motivation). That’s a more comprehensive approach than what most primary care docs can provide in a 15-minute visit.

When It Makes Sense (And When It Doesn’t)

Good candidates for psychiatrist-managed weight loss:

• Patients already under your care with medication-induced weight gain
• Individuals with co-occurring binge eating disorder or ADHD where appetite regulation overlaps with psychiatric treatment
• Patients with obesity and depression/anxiety where metabolic improvement might enhance psychiatric outcomes
• Patients in underserved areas where access to endocrinology or weight management specialists is limited

Refer out when:

• Complex metabolic conditions beyond your comfort level (uncontrolled diabetes, severe cardiovascular disease, prior bariatric surgery complications)
• Patients need comprehensive nutritional counseling or structured weight loss programs you can’t provide
• You’re being asked to prescribe outside an established therapeutic relationship (e.g., purely cash-pay ‘Ozempic clinic’ patients with no psychiatric indication)

Bottom line: If you’re treating the whole patient — integrating weight management into comprehensive psychiatric care — you’re on solid ground. If you’re just trying to cash in on the GLP-1 gold rush without proper training or patient selection, you’re asking for trouble.

Free consultations available with select providers only.

Grow your practice on Klarity

Free to list. Pay only for new patient bookings. Most providers see their first patient within 24 hours.

Start seeing patients

Free to list. Pay only for new patient bookings. Most providers see their first patient within 24 hours.

PMHNP vs. Psychiatrist: Who Can Prescribe What, and Where?

This is where it gets complicated. If you’re a psychiatric nurse practitioner, your ability to prescribe weight loss medications depends entirely on which state you’re licensed in — and the differences are stark.

Psychiatrists (MD/DO): Straightforward Authority

As a physician, you have full prescriptive authority nationwide. You can write for:

• GLP-1 agonists (semaglutide/Wegovy, liraglutide/Saxenda, tirzepatide/Mounjaro) — non-controlled, no special restrictions
• Schedule IV appetite suppressants (phentermine, phendimetrozine) — controlled substances, subject to state-specific rules but generally permitted
• Other FDA-approved obesity medications (orlistat, naltrexone/bupropion combinations)

The only constraints are:

1. State-specific telehealth rules (more on that below)
2. State medical board prescribing standards for obesity treatment (some states have specific protocols you must follow)
3. Standard of care expectations (appropriate workup, monitoring, documentation)

You don’t need a ‘collaborative physician’ or anyone’s permission. Your DEA license covers it.

PMHNPs: A Patchwork of State Rules

If you’re a psychiatric mental health nurse practitioner, welcome to the compliance maze. Your prescribing authority for weight loss meds ranges from ‘fully independent’ to ‘requires physician supervision for everything’ depending on your state.

The Three-Tier System:

Full Practice Authority (FPA) States (~26 states + DC): You can evaluate, diagnose, and prescribe independently without physician oversight. Examples: Arizona, Colorado, Connecticut, Hawaii, Maryland, Montana, Nevada, New Mexico, Oregon, Rhode Island, Washington, Wyoming.

In these states, an experienced PMHNP can prescribe GLP-1s, phentermine, or other weight loss medications on their own authority — assuming it’s within your competency (which, as a psych NP, you’d need to demonstrate through additional training).

Reduced Practice States (~18 states): You need a collaborative agreement with a physician for some aspects of practice, typically prescribing. After meeting experience requirements, some independence may be granted.

• New York: Requires written collaborative agreement initially; after 3,600 hours of practice, NPs can work without a specific collaborating physician (NP Modernization Act). You can prescribe weight loss meds independently after that threshold.
• Illinois: Allows Full Practice Authority after ≥4,000 clinical hours + 250 hours CE. With FPA, you can prescribe including controlled substances (with some consultation requirements for Schedule II initially). Without FPA, you need a collaborative agreement specifying what you can prescribe.
• Pennsylvania: All NPs require a written Collaborative Agreement with a physician. The agreement must list categories of drugs you’re authorized to prescribe. Your collaborating MD’s name must appear on prescriptions alongside yours.

Restricted Practice States (~6 states): You must have physician supervision or delegation for all practice activities, including prescribing.

• Texas: Every NP must have a Prescriptive Authority Agreement (PAA) with a Texas-licensed physician. The PAA details what you can prescribe, requires monthly chart reviews, and mandates face-to-face meetings between you and the supervising physician. No exceptions — Texas has no independent NP practice.
• Florida: APRNs (Florida’s term for NPs) must work under a physician protocol agreement. Florida does have a limited ‘Autonomous Practice’ registration for certain primary care NPs after 3,000+ hours experience, but it excludes psychiatric NPs and prohibits prescribing controlled substances even for autonomous NPs. Translation: As a PMHNP in Florida, you’ll always need an MD collaboration to prescribe weight loss medications.
• Alabama: Extremely restrictive — all NPs must have a collaborative physician, and Alabama limits each physician to collaborating with max 4 NPs. Physicians must co-sign or be available for immediate consultation.

The Hidden Gotcha: Even in FPA States, Insurers May Require Physician Involvement

Here’s what the ‘independent practice’ crowd doesn’t always tell you: Even in states where you’re legally independent, some insurers and pharmacies will push back on NP-only prescriptions for high-cost or controlled medications.

Example: A Washington State PMHNP (full practice authority) prescribes Wegovy. The pharmacy calls asking for ‘the supervising doctor’s name’ because their system flags expensive GLP-1s for additional review. Or a prior authorization from Blue Cross requires a physician signature even though state law doesn’t.

This isn’t universal, but it’s common enough that many telehealth platforms serving multiple states maintain physician medical directors regardless of NP autonomy — to smooth billing, PA approvals, and pharmacy acceptance.

Specialty Scope: Can a Psych NP Prescribe for Weight Loss?

Separate from state scope-of-practice is the question of specialty competency. You were trained as a psychiatric mental health NP — does prescribing for obesity fall within that?

Legally, most state nurse practice acts don’t rigidly compartmentalize by specialty. Scope is defined by your education, training, and competency. However, if you start running a weight loss clinic without any psychiatric overlap, a state board could question whether you’re practicing outside your certified specialty.

Safe approaches:

• Prescribe weight loss meds to patients already under your psychiatric care where there’s overlap (e.g., treating depression + obesity, managing antipsychotic side effects)
• Obtain additional certification or training in obesity medicine (continuing ed, focused coursework)
• Work under a collaborative agreement where the supervising physician has expertise in weight management (this adds legitimacy)

Risky approach:

• Marketing yourself as a ‘weight loss specialist’ with no psychiatric connection, seeing patients purely for Ozempic, when your only credentials are psychiatric NP training. A nursing board could view this as scope creep.

Bottom line for PMHNPs: Know your state’s rules cold, get proper training, and when in doubt, collaborate with a physician experienced in obesity treatment.

Telehealth Prescribing: Where Federal Permission Meets State Prohibition

Telehealth has made weight loss treatment accessible to millions — but it’s also created a compliance trap that’s caught even large companies off guard. Here’s what you need to know.

The Federal Waiver: Prescribing Controlled Substances via Telehealth

Pre-COVID, the Ryan Haight Act required an in-person exam before prescribing any controlled substance. During the pandemic, the DEA waived this requirement. That waiver has been extended through December 31, 2025 (and likely beyond, given bipartisan support for telehealth access).

Under the current federal rule, you can prescribe Schedule II-V controlled substances — including phentermine (Schedule IV), the most common weight loss medication — via telehealth to patients you’ve never seen in person, as long as you conduct an appropriate evaluation (typically video visit) and maintain proper documentation.

Great, right? Not so fast.

The State Override Problem

Here’s the trap: Federal permission doesn’t override stricter state laws. The DEA explicitly states that telehealth prescribing is only legal if it complies with both federal and state requirements.

Florida: The ‘No Controlled Substances via Telehealth’ Rule

Florida law (F.S. 456.47) prohibits prescribing controlled substances through telehealth except for: psychiatric disorders, inpatient/hospice care, acute pain, or addiction treatment. Weight loss is not on that list.

Translation: If you’re doing telehealth to Florida patients, you cannot prescribe phentermine remotely — even though federal law allows it. You can prescribe GLP-1s (semaglutide, liraglutide) because they’re not controlled substances, but the Schedule IV appetite suppressants are off-limits unless there’s an in-person component.

Some providers try to argue that if the patient has a co-occurring psychiatric diagnosis (depression + obesity), it fits the ‘psychiatric disorder’ exemption. This is legally murky and risky. Florida regulators haven’t issued clear guidance, and you don’t want to be the test case.

Alabama: Similar In-Person Requirement

Alabama law requires an initial in-person exam (or physician physically present with patient) before prescribing controlled substances. Like Florida, this blocks purely remote phentermine prescriptions. Alabama is also a very restrictive state for NP practice (4-NP cap per physician, mandatory collaboration) — making telehealth weight loss operationally challenging there.

Other State Quirks:

• Idaho: Requires in-person exam for controlled weight-loss drugs
• South Carolina: Has stringent telemedicine standards that effectively limit controlled substance prescribing remotely
• Texas: No explicit controlled-substance telehealth ban for weight loss (the federal waiver applies), but Texas does prohibit prescribing Schedule II stimulants for obesity. Phentermine (Schedule IV) is allowed via telehealth with proper documentation and PMP check.

The Bottom Line: About 42 states currently align with federal telehealth flexibilities for controlled substances. A handful (Florida, Alabama, and a few others) impose stricter rules that can trap you into non-compliance even when you think you’re following federal law.

Non-Controlled GLP-1s: Mostly Green Light

The good news: GLP-1 agonists (Wegovy, Ozempic/semaglutide, Saxenda, Mounjaro) are not controlled substances. In most states, you can prescribe them via telehealth after a proper video evaluation with no additional restrictions.

State-specific exceptions:

• Mississippi: Banned off-label prescribing of GLP-1s for weight loss. You must use FDA-approved obesity versions (Wegovy, not Ozempic, for non-diabetics). The state medical board will discipline providers using Ozempic solely for weight loss in non-diabetic patients.

Establishing a Valid Patient Relationship

Most states require a ‘valid patient-provider relationship’ before prescribing. Post-pandemic, nearly all states accept that a live video consultation establishes this relationship if the evaluation is equivalent to an in-person exam.

What counts as adequate:

• Live video visit (not just phone or text-based questionnaire)
• Comprehensive history including weight history, prior attempts at weight loss, comorbidities
• Visual assessment (observing the patient, assessing for signs of metabolic disease if visible)
• Review of recent vital signs (patients can self-report weight, blood pressure; some platforms send them a scale/BP cuff or require lab visits)
• Documentation of BMI calculation and medical necessity

What doesn’t count (and has led to license discipline):

• Purely asynchronous questionnaire-based prescribing
• Text-only or email-only consults
• Skipping evaluation and prescribing based solely on patient request

Case example: In May 2023, a Mississippi physician had his license suspended for prescribing Ozempic through an instant-messaging platform with no audio/video interaction. The medical board deemed it failure to establish a proper relationship and conduct a physical exam. Don’t be that doctor.

State-Specific Clinical Rules for Weight Loss Prescribing

Beyond telehealth modality, some states impose clinical practice standards for obesity treatment. These apply whether you’re seeing patients in-person or via video.

Florida: The Most Detailed Requirements

Florida Board of Medicine Rule 64B15-14.004 (and parallel rules for DOs and others) sets strict protocols:

1. BMI Criteria: Patient must have BMI ≥30, or BMI ≥27 with serious comorbidity (diabetes, hypertension, dyslipidemia, sleep apnea). Document this before prescribing.

2. Initial Evaluation: Comprehensive history and physical exam required. The rule allows an APRN or PA to conduct this under delegation, but it must be thorough (rule out secondary causes of obesity like hypothyroidism, Cushing’s, etc.). Labs should include at minimum: fasting glucose, lipid panel, TSH. Document all findings.

3. Informed Consent: Written consent discussing risks, benefits, alternatives. Florida provides a template ‘Weight-Loss Consumer Bill of Rights’ brochure that must be given to patients.

4. Follow-Up: Face-to-face follow-up at least every 3 months while on medication. This can be telehealth visits, but you must document weight, blood pressure, side effects, and treatment response every 90 days. Missing this interval can trigger board discipline.

5. Prescription Limits: No automatic refills indefinitely. Each follow-up should reassess need for continued therapy.

Florida’s rule is a response to past ‘diet pill mills’ — regulators take this seriously. Chart audits happen, and clinics have been fined for not meeting the 3-month follow-up requirement or prescribing to patients below BMI thresholds.

New Jersey: Comprehensive Workup Required

New Jersey Board of Medical Examiners requires:

• Complete history, physical exam, appropriate labs
• Assessment for underlying psychiatric conditions (this plays to your strength as a psychiatrist/PMHNP — you’re already doing this)
• Treatment or stabilization of psychiatric issues prior to or alongside weight-loss medication (don’t start a depressed patient on phentermine without addressing the depression — could worsen anxiety, insomnia)
• Documentation of nutritional counseling, exercise plan, and behavior modification recommendations (not just prescribing pills)

For telehealth providers, this means you need to either provide or refer for nutrition/exercise counseling. Many platforms partner with health coaches or RDs to meet this requirement.

Virginia: Monthly Follow-Ups Initially

Virginia Board of Medicine mandates a follow-up within 30 days of starting weight-loss medication, then at least monthly for the first few months. After stabilization, quarterly is acceptable. Prescribers must also document a diet and exercise program.

Virginia’s rule targets controlled substances primarily, so it’s most relevant for phentermine. For GLP-1s, best practice is still frequent early check-ins (patients often have significant GI side effects in the first month that need dose adjustment).

Texas: Standard of Care + PMP Checks

Texas doesn’t have a specific ‘obesity prescribing rule’ like Florida, but:

• All prescribers must use good clinical judgment (document indication, BMI, trial of lifestyle measures)
• For controlled substances: Check the Texas Prescription Monitoring Program (PMP) before prescribing. Texas requires PMP checks for opioids, benzos, barbiturates, and carisoprodol by law, and it’s best practice for phentermine.
• NPs must have their Prescriptive Authority Agreement explicitly authorize weight-loss medications (some PAAs are overly narrow; make sure yours lists appetite suppressants if you’re prescribing them)

California: No Specific Obesity Rules, But Standard of Care Applies

California hasn’t enacted Florida-style specific rules, but the Medical Board expects prescribers to follow national guidelines:

• Appropriate indication (BMI criteria)
• Informed consent
• Monitoring for side effects and efficacy
• Not prescribing indefinitely without follow-up

California’s telehealth laws are permissive — no extra restrictions on remote prescribing as long as standard of care is met.

Compounding Semaglutide: Risky Territory

During the Wegovy shortage, compounding pharmacies started producing semaglutide. Some telehealth companies pivoted to compounded versions to offer cheaper options. This is now under intense scrutiny.

• FDA and state boards (like Alabama) have warned that using non-FDA-registered compounding facilities or non-pharmaceutical-grade ingredients is prohibited
• Some compounders used ‘semaglutide sodium’ (a salt form not FDA-approved) instead of the approved semaglutide base — this is illegal
• Compounding is only lawful during a drug shortage and must use proper ingredients from FDA-registered suppliers

Advice: If you’re prescribing through a telehealth platform, verify they’re using FDA-approved brand-name GLP-1s or legally compounded versions from 503B outsourcing facilities. Don’t prescribe compounded semaglutide from sketchy sources — you can face liability if a patient is harmed or if regulators investigate.

PDMP Checks: Don’t Skip This Step

Almost every state requires checking the Prescription Drug Monitoring Program before prescribing controlled substances. For phentermine:

• Florida: Mandatory E-FORCSE check before each controlled substance prescription
• Texas: Must check PMP for Schedule II-IV (technically focused on opioids/benzos, but phentermine is C-IV — best practice is to check)
• New York: Must check I-STOP before prescribing Schedule II, III, or IV (includes phentermine)
• Illinois: PMP registration required; must check for Schedule II (less clear-cut for C-IV like phentermine, but it’s good practice)
• Pennsylvania: PMP check encouraged but not universally mandated for all C-IV; check your local policy

Telehealth EHR systems should integrate PDMP access. It takes 30 seconds and protects you from unknowingly prescribing to someone doctor-shopping or with contraindications flagged in the database.

What Insurance Covers (And How to Actually Get Paid)

Weight loss medication management used to be a cash-pay game. That’s rapidly changing — and it creates new revenue opportunities for providers who navigate the reimbursement landscape correctly.

GLP-1 Insurance Coverage: The Expanding Universe

Private Insurance:Most major commercial plans now cover FDA-approved GLP-1s for obesity (Wegovy, Saxenda) with prior authorization. Criteria typically include:

• BMI ≥30, or BMI ≥27 with comorbidity (diabetes, hypertension, dyslipidemia)
• Documentation of lifestyle modification attempts (diet, exercise, behavioral therapy for X months)
• Sometimes: requirement for participation in a weight management program

Prior Authorization Tips:

• Be prepared to attest to the patient’s BMI (with date of measurement)
• List comorbid conditions explicitly (if they’re on metformin for prediabetes, call that out)
• Document previous weight loss attempts (even if it’s patient report of ‘tried dieting, regained weight’)
• Some PAs ask for your credentials — having obesity medicine certification or relevant experience helps

Quantity Limits:Some insurers (like certain BCBS plans) introduced 30-day supply limits for GLP-1s in 2024. Initial prescriptions get a 1-month fill, then the patient must follow up before refills are approved. This is to combat waste (patients stopping due to side effects after a week but with a 90-day supply already filled).

Operationally: You’ll need to see these patients monthly at first, document tolerability/response, then insurers typically allow 90-day supplies once stable.

Medicare and Medicaid: The Game-Changer

Historically, Medicare Part D excluded weight loss drugs (classified them with cosmetic treatments). In November 2025, that changed: the administration announced Medicare will begin covering anti-obesity medications following price negotiations with manufacturers.

Implementation is rolling out in early 2026. What this means:

• Medicare beneficiaries with BMI ≥30 (or ≥27 + comorbidity) will have coverage for Wegovy, Mounjaro, and likely Saxenda
• Prior authorization will still apply (Medicare Advantage plans will set their own PA criteria, but must cover if meeting medical necessity)
• This affects millions of seniors — huge demand spike coming for providers

Medicaid: Coverage varies by state (states aren’t required to cover obesity drugs, unlike diabetes meds). However, many state Medicaids are adding coverage:

• Illinois Medicaid covers some weight loss meds with PA
• New York Medicaid has limited coverage (proposed expansion pending)
• California Medicaid (Medi-Cal) — selective coverage for certain populations
• Texas, Florida Medicaid — historically very limited; watch for policy updates post-Medicare change

For providers: If you serve Medicare/Medicaid populations, get familiar with local MAC or state Medicaid coverage policies for obesity treatment. This could represent a significant revenue stream that didn’t exist a year ago.

Billing for the Visits: E/M Codes and Obesity Counseling

For Psychiatrists:You’ll bill standard E/M codes or psychiatric codes for the visit itself:

• 99202-99205 (new patient office visits) — use appropriate level based on complexity
• 99211-99215 (established patient office visits) — for follow-ups, often 99213 (low complexity, ~15 minutes) or 99214 (moderate, ~25 minutes) depending on what you do
• 90792 (psychiatric diagnostic evaluation) — if combining psychiatric assessment with medication management for a new patient, ~$200 reimbursement from Medicare
• 90833, 90836, 90838 (psychotherapy add-on codes) — if you’re also providing therapy during the visit (e.g., behavioral counseling for emotional eating)

If you’re doing a 15-20 minute video visit primarily for med management (adjusting semaglutide dose, reviewing side effects, checking weight), you’d typically code 99213 (est. patient, low-moderate complexity). Medicare pays ~$75-95 for this depending on region; commercial payers similar or slightly higher.

For PMHNPs:You code identically, but reimbursement is typically 85% of physician rates from Medicare when billed under your own NPI. Some commercial payers also pay at 85-90% of MD rates. Exception: Illinois Medicaid reimburses NPs at 100% of physician rates (state policy to encourage NP utilization).

Incident-To Billing (Tricky for Telehealth):Some practices have NPs bill ‘incident-to’ the physician (under the MD’s NPI) to capture 100% reimbursement. This requires the physician to have established the patient initially and be immediately available. In pure telehealth settings where you’re in different states, incident-to often doesn’t apply. Most telehealth NPs bill under their own credentials.

Obesity Counseling Codes:Medicare has specific G-codes for obesity counseling:

• G0447: Face-to-face behavioral counseling for obesity, 15 minutes (for patients with BMI ≥30)
• G0473: Group obesity counseling

These are typically used by primary care or dietitians. Psychiatrists could use G0447 if providing focused dietary counseling, but in practice, you’d more likely bill your standard E/M codes that already encompass counseling. If you’re spending significant time on nutrition/exercise education, billing a higher-level E/M code with counseling noted in documentation is appropriate.

Telehealth Payment Parity: State-by-State

States with Telehealth Parity Laws (must reimburse telehealth equal to in-person):

• California: Full parity since 2021 for private plans
• New York: Parity law effective Jan 2022
• Illinois: Parity required by Telehealth Act
• Pennsylvania: Parity for certain services (mental health has strong parity; general medical services still variable)

Texas: Has coverage parity (insurers must cover telehealth if they cover the service in-person) but historically didn’t mandate equal payment. As of 2023-25, there’s strong push (Texas Medical Association, legislation) for payment parity. Check with individual payers — many voluntarily pay telehealth visits at par now.

Florida: No universal parity statute for commercial insurance. Some payers pay equal, others may pay telehealth at 80-90% of in-person rates. Florida Medicaid does cover telehealth.

Medicare: Temporary COVID waivers made telehealth reimbursement equal to office visits through at least 2025 (likely extending further). Medicare pays telehealth mental health visits at the same rate as in-office, and this includes tele-psychiatry medication management.

Practical Implication:In most states, a 15-minute med management video visit for weight loss will reimburse roughly the same as if the patient sat in your office. This makes telehealth financially sustainable. If you’re in a non-parity state, budget for potentially lower reimbursement (or focus on states with parity).

Cash Pay vs Insurance: Economics

Many weight loss telehealth companies started as direct-to-consumer cash-pay models:

• Patient pays $99-199/month membership
• Includes medication consults and prescription (sometimes meds included if using compounded versions)

This works well when:

• Patients are affluent and willing to pay out-of-pocket (especially for trendy GLP-1s)
• You’re offering fast access without insurance hassles
• Medications are compounded (cheaper than brand-name)

The problem: Brand-name Wegovy costs ~$1,300/month without insurance. Even with a $50 consult, patients face $1,350/month total. That limits your market to high-earners.

Now that insurance is covering more, patients increasingly want to use their benefits. For providers, this means:

• Credentialing with insurers (more admin overhead)
• Dealing with prior authorizations (some platforms have PA coordinators to handle this)
• But you can serve a much larger patient base (people who can afford $50-100 copay, not $1,300)

If you join a platform like Klarity Health: The platform typically handles credentialing and billing. You see the patient, document the visit, submit your note, and get paid per visit. Patient acquisition is handled by the platform. You’re not spending $500/patient on Google Ads or hoping your SEO pays off in 8 months — you pay a platform fee only when a qualified patient books with you.

This is the smart economics: no upfront marketing spend, no wasted ad clicks, just patients ready to see you.

State-by-State Compliance Cheat Sheet

Here’s what you need to know for each priority state:

California

• NP Scope: Transitioning to independent practice (AB 890). Full independence starts Jan 2026 for ‘104’ NPs. Until then, standardized procedures required.
• MD Requirement: Corporate Practice of Medicine means clinics need physician ownership/oversight
• Prescribing: No special state obesity rules; follow standard of care. Telehealth permitted.
• Gotcha: Even independent NPs can’t prescribe controlled substances for weight loss until they have independent furnishing privileges

Texas

• NP Scope: All NPs require Prescriptive Authority Agreement with TX physician. No independence.
• MD Requirement: Mandatory medical director; PAA must explicitly authorize weight loss meds
• Prescribing: Phentermine allowed (check PMP). No Schedule II stimulants for obesity. Telehealth OK federally; state doesn’t prohibit.
• Gotcha: One physician can supervise max 7 NPs outside hospitals. Monthly chart reviews and meetings required.

Florida

• NP Scope: Protocol agreement required (even ‘autonomous’ NPs can’t prescribe controlled substances). PMHNPs never independent.
• MD Requirement: Health Care Clinic Act requires licensed clinic with MD medical director
• Prescribing: Detailed Board rules — BMI criteria, informed consent, 3-month follow-ups mandatory. Cannot prescribe controlled substances via telehealth for weight loss (state law prohibits it). GLP-1s OK via telehealth.
• Gotcha: Most restrictive state. Missing follow-up deadlines or prescribing phentermine remotely = license risk.

New York

• NP Scope: Collaborative agreement initially; after 3,600 hours, can practice independently
• MD Requirement: No strict CPOM; NPs can own practices
• Prescribing: No specific obesity rules. Must check I-STOP for controlled substances. Follow standard of care.
• Gotcha: NYC market is competitive; differentiate by offering integrated psychiatric + metabolic care

Pennsylvania

• NP Scope: Collaborative agreement required for all NPs (no FPA yet)
• MD Requirement: Collaborating physician’s name must appear on prescriptions
• Prescribing: No special state obesity treatment rules. Collaboration agreement should explicitly authorize weight loss meds if including controlled substances.
• Gotcha: No telehealth payment parity statute (yet); some insurers pay less for telehealth visits

Illinois

• NP Scope: FPA available after 4,000 hours + 250 CE hours. With FPA, can prescribe independently including controlled substances.
• MD Requirement: Only needed if NP doesn’t have FPA
• Prescribing: No specific state obesity regulations. Must check PMP. With FPA, broad authority.
• Gotcha: Even FPA NPs have some

Source:

• https://www.medicaldirectorco.com/collaborative-physician-cost-weight-loss-telehealth/#:~:text=The%20answer%20is%20almost%20always,yes
• https://www.medicaldirectorco.com/collaborative-physician-cost-weight-loss-telehealth/#:~:text=Nurse%20Practitioners%20
• https://journals.lww.com/tnpj/fulltext/2024/01000/36thannualaprnlegislativeupdate__improving.6.aspx#:~:text=The%20Pennsylvania%20BON%20grants%20CRNPs%2C,more%20physicians%20to%20deliver%20healthcare
• https://journals.lww.com/tnpj/fulltext/2024/01000/36thannualaprnlegislativeupdate__improving.6.aspx#:~:text=The%20Illinois%20Department%20of%20Financial,collaborative%20agreement%20following%20a%20TTP
• https://rxagent.co/blog/telehealth-compliance-trap#:~:text=The%20DEA%20gave%20us%20the,evaluation%20at%20the%20federal%20level
• https://rxagent.co/blog/telehealth-compliance-trap#:~:text=Despite%20federal%20DEA%20waivers%20extending,traps%20for%20digital%20health%20providers
• https://rxagent.co/blog/telehealth-compliance-trap#:~:text=1.%20Florida%3A%20The%20%22No,for%20Stimulants
• https://www.mondaq.com/unitedstates/healthcare/1447512/a-changing-regulatory-and-reimbursement-landscape-for-weight-loss-drugs#:~:text=New%20Jersey%20law%20requires%20that,and%20identify%20the%20risks%20associated
• https://drlewis.com/glp-1-medications-psychiatry/#:~:text=You%20know%20these%20drugs,disorders%2C%20and%20possibly%20depression%20itself
• https://drlewis.com/glp-1-mental-health/#:~:text=Now%20let%E2%80%99s%20talk%20about%20potential,where%20things%20get%20really%20interesting